Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 6, 2021; 9(25): 7498-7503
Published online Sep 6, 2021. doi: 10.12998/wjcc.v9.i25.7498
Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report
Li Zhang, Jing Wang, Ling-Zhi Cui, Kai Wang, Ming-Ming Yuan, Rong-Rong Chen, Li-Jiao Zhang
Li Zhang, Jing Wang, Ling-Zhi Cui, Li-Jiao Zhang, Department of Cadre Health, Shanxi Provincial Cancer Hospital, Taiyuan 030013, Shanxi Province, China
Kai Wang, Ming-Ming Yuan, Rong-Rong Chen, Department of Medicine, Geneplus-Beijing, Beijing 102206, China
Author contributions: Zhang L reviewed and searched the literature, analyzed and interpreted the imaging findings, drafted the manuscript, and gave critical comments; Wang J and Cui LZ collected the clinical data; Wang K and Yuan MM reviewed the literature; Chen RR gave critical comments; Zhang LJ contributed to the revision of the manuscript; all authors approved the version to be submitted.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: Wang K, Yuan MM, and Chen RR are current employees of Geneplus-Beijing. The other authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Jiao Zhang, MM, Chief Physician, Professor, Department of Cadre Health, Shanxi Provincial Cancer Hospital, No. 3 Employee Xincun, Xinghualing District, Taiyuan 030013, Shanxi Province, China. zljsx66@126.com
Received: February 2, 2021
Peer-review started: February 2, 2021
First decision: May 11, 2021
Revised: May 24, 2021
Accepted: July 19, 2021
Article in press: July 19, 2021
Published online: September 6, 2021
Core Tip

Core Tip: The clinical evidence for successful off-label use of targeted drugs for lung adenocarcinoma patients following progression on multiple lines of treatment is still lacking now. Herein, we describe the identification of a germline BRCA2 mutation in a lung adenocarcinoma patient. The patient had multiple refractory brain metastases and received olaparib combined with gefitinib and recombinant human endostatin following progression on multiple lines of treatment, with a progression-free survival of 13.5 mo. This case provides unequivocal clinical evidence for the off-label use of olaparib in lung adenocarcinoma patients with a BRCA mutation after disease progression.